[go: up one dir, main page]

HK1219413A1 - 利妥昔单抗诱导疗法继而醋酸格拉替雷疗法 - Google Patents

利妥昔单抗诱导疗法继而醋酸格拉替雷疗法 Download PDF

Info

Publication number
HK1219413A1
HK1219413A1 HK16107400.1A HK16107400A HK1219413A1 HK 1219413 A1 HK1219413 A1 HK 1219413A1 HK 16107400 A HK16107400 A HK 16107400A HK 1219413 A1 HK1219413 A1 HK 1219413A1
Authority
HK
Hong Kong
Prior art keywords
subject
disease
amount
glatiramer acetate
therapy
Prior art date
Application number
HK16107400.1A
Other languages
English (en)
Inventor
Vollmer Timothy
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51527961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1219413(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HK1219413A1 publication Critical patent/HK1219413A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
HK16107400.1A 2013-03-12 2014-03-12 利妥昔单抗诱导疗法继而醋酸格拉替雷疗法 HK1219413A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361778016P 2013-03-12 2013-03-12
US61/778,016 2013-03-12
PCT/US2014/025075 WO2014165280A1 (en) 2013-03-12 2014-03-12 Rituximab induction therapy followed by glatiramer acetate therapy

Publications (1)

Publication Number Publication Date
HK1219413A1 true HK1219413A1 (zh) 2017-04-07

Family

ID=51527961

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16107400.1A HK1219413A1 (zh) 2013-03-12 2014-03-12 利妥昔单抗诱导疗法继而醋酸格拉替雷疗法
HK16106268.4A HK1218253A1 (zh) 2013-03-12 2014-03-12 利妥昔单抗诱导疗法继而醋酸格拉替雷疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16106268.4A HK1218253A1 (zh) 2013-03-12 2014-03-12 利妥昔单抗诱导疗法继而醋酸格拉替雷疗法

Country Status (18)

Country Link
US (3) US20160022811A1 (zh)
EP (1) EP2968559A4 (zh)
JP (1) JP2016512552A (zh)
KR (1) KR20150138240A (zh)
CN (1) CN105188751A (zh)
AR (1) AR095372A1 (zh)
AU (1) AU2014248524A1 (zh)
BR (1) BR112015022538A2 (zh)
CA (1) CA2903127A1 (zh)
CL (1) CL2015002597A1 (zh)
EA (1) EA201591687A1 (zh)
HK (2) HK1219413A1 (zh)
IL (1) IL240355A0 (zh)
MX (1) MX2015012156A (zh)
PE (1) PE20151937A1 (zh)
TW (1) TW201521757A (zh)
WO (1) WO2014165280A1 (zh)
ZA (1) ZA201507489B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2630962T3 (en) 2009-08-20 2018-07-23 Yeda Res & Development Company Ltd Low-frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
NZ703122A (en) 2010-10-11 2016-06-24 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
EA201490749A1 (ru) 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз Лтд. Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат
NZ630421A (en) 2012-10-10 2018-07-27 Teva Pharma Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US9744920B2 (en) * 2015-04-21 2017-08-29 Mazda Motor Corporation Noise insulation structure of cabin floor
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
SI3506921T1 (sl) 2016-08-31 2023-10-30 Mapi Pharma Ltd. Depojski sistemi, ki vsebujejo glatiramer acetat
JP7602322B2 (ja) 2017-03-26 2024-12-18 マピ ファーマ リミテッド 進行型の多発性硬化症を治療するためのグラチラマーデポシステム
US20220213210A1 (en) * 2017-12-05 2022-07-07 Mabion Sa Combination therapy of multiple sclerosis comprising a cd20 ligand
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) * 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0510915A (pt) * 2004-06-04 2007-11-13 Genentech Inc método para o tratamento da esclerose múltipla e artigo manufaturado
US20070161566A1 (en) * 2006-01-11 2007-07-12 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US20130035390A1 (en) * 2010-01-13 2013-02-07 Ramot At Tel-Aviv University Ltd. Treatment of multiple sclerosis
WO2012103365A1 (en) * 2011-01-28 2012-08-02 Oregon Health & Science University Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases

Also Published As

Publication number Publication date
CL2015002597A1 (es) 2016-04-15
EP2968559A1 (en) 2016-01-20
HK1218253A1 (zh) 2017-02-10
EA201591687A1 (ru) 2016-07-29
EP2968559A4 (en) 2016-11-02
AR095372A1 (es) 2015-10-14
JP2016512552A (ja) 2016-04-28
TW201521757A (zh) 2015-06-16
IL240355A0 (en) 2015-09-24
CA2903127A1 (en) 2014-10-09
US20170143824A1 (en) 2017-05-25
US20140271630A1 (en) 2014-09-18
MX2015012156A (es) 2015-11-30
PE20151937A1 (es) 2016-01-15
KR20150138240A (ko) 2015-12-09
BR112015022538A2 (pt) 2017-07-18
CN105188751A (zh) 2015-12-23
ZA201507489B (en) 2017-01-25
US20160022811A1 (en) 2016-01-28
WO2014165280A1 (en) 2014-10-09
AU2014248524A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
HK1219413A1 (zh) 利妥昔单抗诱导疗法继而醋酸格拉替雷疗法
MX355065B (es) Método y dispositivo para conmutación de cámaras.
AR088458A1 (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod
BR112016029713A8 (pt) uso de uma carboximetilcelulose reticulada e uso de um agente gelificante
MX2023003337A (es) Uso de cannabinoides en el tratamiento de epilepsia.
HK1205941A1 (zh) 联合使用拉喹莫德和富马酸二甲酯治疗多发性硬化症的方法
MY197886A (en) Peptide having anti-diabetic and anti-obesity effects, and use thereof
HK1198279A1 (zh) 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
PH12015501994A1 (en) Antibodies that bind il-23
WO2012149186A3 (en) Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
HK1218865A1 (zh) 用於降低多发性硬化症中丘脑损伤的拉喹莫德
WO2015040182A3 (en) Amylin analogues
HK1213830A1 (zh) 用於预测醋酸格拉替雷临床反应的生物标志物
WO2015003122A3 (en) Regulation of glucose metabolism using anti-cgrp antibodies
WO2018071504A3 (en) Methods of treating diseases with il-23a antibody
HK1209672A1 (zh) 用拉喹莫德和氨吡啶的组合治疗多发性硬化症
PH12015502100A1 (en) Reducing the risk of autoimmune disease
WO2014070971A3 (en) Somatostatin-dopamine chimeric analogs
HK1223855A1 (zh) 拉喹莫德和氟吡汀组合物用於治疗多发性硬化症
HK1208356A1 (zh) 維持，治療或改善認知功能的方法
HK1223854A1 (zh) 通过阿仑单抗诱导随後通过拉喹莫德疗法来治疗多发性硬化症
Matalon et al. The discoverer of Canavan syndrome gene: how problems of diagnosis and treatment are being changed over time
Shekhovtsova The functional state of the pancreas in patients with type 2 diabetes mellitus with different phenotype
Davis Fentanyl/hydrocodone
Uchiyama Angioedema and urticaria in an elderly patient: case report